ORCID – ResearcherID

(+33) 03 88 12 75 37

(+33) 03 88 27 53 64




Liste des publications :


Jannier, S., Kemmel, V., Sebastia Sancho, C., Chammas, A., Sabo, A.-N., Pencreach, E., Farace, F., Chenard, M. P., Lhermitte, B., Geoerger, B., Aerts, I., Frappaz, D., Leblond, P., André, N., Ducassou, S., Corradini, N., Bertozzi, A. I., Guérin, E., Vincent, F., … Entz-Werle, N. (2020). SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers. Cancers, 12(10).
Beau-Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J.-P., Bringuier, P.-P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., Denis, M., Hofman, P., Lacave, R., Melaabi, S., Langlais, A., Missy, P., Morin, F., Moro-Sibilot, D., Barlesi, F., … French Cooperative Thoracic Intergroup (IFCT). (2019). Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer (Amsterdam, Netherlands), 140, 19–26.
Coliat, P., Ramolu, L., Jégu, J., Gaiddon, C., Jung, A. C., & Pencreach, E. (2019). Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC. Cancers, 11(10).
Reita, D., Bour, C., Benbrika, R., Groh, A., Pencreach, E., Guérin, E., & Guenot, D. (2019). Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers, 11(10).
Rimelen, V., Ahle, G., Pencreach, E., Zinniger, N., Debliquis, A., Zalmaï, L., Harzallah, I., Hurstel, R., Alamome, I., Lamy, F., Voirin, J., & Drénou, B. (2019). Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathologica Communications, 7(1), 43.
Davidson, G., Coassolo, S., Kieny, A., Ennen, M., Pencreach, E., Malouf, G. G., Lipsker, D., & Davidson, I. (2019). Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations. The Journal of Investigative Dermatology, 139(8), 1769–1778.
Mammadova-Bach, E., Rupp, T., Spenlé, C., Jivkov, I., Shankaranarayanan, P., Klein, A., Pisarsky, L., Méchine-Neuville, A., Cremel, G., Kedinger, M., De Wever, O., Ambartsumian, N., Robine, S., Pencreach, E., Guenot, D., Simon-Assmann, P., Goetz, J. G., Orend, G., & Lefebvre, O. (2018). Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma. Biology of the Cell, 110(8), 178–195.
Emprou, C., Le Van Quyen, P., Jégu, J., Prim, N., Weingertner, N., Guérin, E., Pencreach, E., Legrain, M., Voegeli, A.-C., Leduc, C., Mennecier, B., Falcoz, P.-E., Olland, A., Santelmo, N., Quoix, E., Massard, G., Guenot, D., Chenard, M.-P., & Beau-Faller, M. (2018). SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients. Cancer Medicine, 7(7), 3278–3291.
Nguyen, A., Moussallieh, F. M., Mackay, A., Cicek, A. E., Coca, A., Chenard, M. P., Weingertner, N., Lhermitte, B., Letouzé, E., Guérin, E., Pencreach, E., Jannier, S., Guenot, D., Namer, I. J., Jones, C., & Entz-Werlé, N. (2017). Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition. Oncotarget, 8(42), 71597–71617.
Romain, B., Benbrika-Nehmar, R., Marisa, L., Legrain, M., Lobstein, V., Oravecz, A., Poidevin, L., Bour, C., Freund, J.-N., Duluc, I., Guenot, D., & Pencreach, E. (2017). Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration. Oncotarget, 8(24), 38351–38366.
Hanns, E., Job, S., Coliat, P., Wasylyk, C., Ramolu, L., Pencreach, E., Suarez-Carmona, M., Herfs, M., Ledrappier, S., Macabre, C., Abecassis, J., Wasylyk, B., & Jung, A. C. (2015). Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncology, 51(9), 848–856.
Romain, B., Hachet-Haas, M., Rohr, S., Brigand, C., Galzi, J.-L., Gaub, M.-P., Pencreach, E., & Guenot, D. (2014). Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Molecular Cancer, 13, 58.
Derbal-Wolfrom, L., Pencreach, E., Saandi, T., Aprahamian, M., Martin, E., Greferath, R., Tufa, E., Choquet, P., Lehn, J.-M., Nicolau, C., Duluc, I., & Freund, J.-N. (2013). Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene, 32(36), 4313–4318.
Nedeva, I., Koripelly, G., Caballero, D., Chièze, L., Guichard, B., Romain, B., Pencreach, E., Lehn, J.-M., Carlier, M.-F., & Riveline, D. (2013). Synthetic polyamines promote rapid lamellipodial growth by regulating actin dynamics. Nature Communications, 4, 2165.
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., … Boige, V. (2013). Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Medicine, 10(5), e1001453.
Nguyen, A., Lasthaus, C., Guerin, E., Marcellin, L., Pencreach, E., Gaub, M.-P., Guenot, D., & Entz-Werle, N. (2013). Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse. Cancers, 5(2), 662–675.
Guérin, E., Raffelsberger, W., Pencreach, E., Maier, A., Neuville, A., Schneider, A., Bachellier, P., Rohr, S., Petitprez, A., Poch, O., Moras, D., Oudet, P., Larsen, A. K., Gaub, M.-P., & Guenot, D. (2012). In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Molecular Medicine (Cambridge, Mass.), 18, 83–94.
Pencreach, E., Guérin, E., Nicolet, C., Lelong-Rebel, I., Voegeli, A.-C., Oudet, P., Larsen, A. K., Gaub, M.-P., & Guenot, D. (2009). Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15(4), 1297–1307.
Weber, J.-C., Meyer, N., Pencreach, E., Schneider, A., Guérin, E., Neuville, A., Stemmer, C., Brigand, C., Bachellier, P., Rohr, S., Kedinger, M., Meyer, C., Guenot, D., Oudet, P., Jaeck, D., & Gaub, M.-P. (2007). Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes. International Journal of Cancer. Journal International Du Cancer, 120(3), 524–532.
Guenot, D., Guérin, E., Aguillon-Romain, S., Pencreach, E., Schneider, A., Neuville, A., Chenard, M.-P., Duluc, I., Du Manoir, S., Brigand, C., Oudet, P., Kedinger, M., & Gaub, M.-P. (2006). Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability. The Journal of Pathology, 208(5), 643–652.